文献速递胸部肿瘤

肺腺癌PD-L1表达的临床与分子相关性

Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas.
PubMed 文献 · Ann Oncol · 2020-02-06

该研究对1586例肺腺癌患者同一样本进行PD-L1检测和靶向二代测序,分析分子特征与PD-L1表达的关系及对ICI疗效的影响。发现PD-L1表达因样本部位而异,KRAS、TP53、MET突变与PD-L1高表达相关,EGFR和STK11突变与PD-L1阴性相关,且EGFR和STK11突变削弱PD-L1对ICI疗效的预测价值。

要点

  • PD-L1表达及对ICI疗效的预测价值因样本部位而异。
  • KRAS、TP53、MET突变与PD-L1高表达相关。
  • EGFR和STK11突变与PD-L1阴性相关并削弱其预测价值。

核心结论

  • PD-L1表达及与ICI疗效的关联因组织样本部位而异。
  • 特定分子特征与PD-L1差异表达相关,可能影响PD-L1对ICI疗效的预测能力。

研究设计与样本

  • 评估1586例肺腺癌患者,对同一样本组织进行PD-L1检测和靶向二代测序(MSK-IMPACT)。
  • 比较不同PD-L1亚组的临床和分子特征,并在接受抗PD-(L)1治疗的患者中评估相互作用对疗效的影响。

主要发现

  • PD-L1阴性在原发样本中比转移样本更常见(P < 0.001)。
  • PD-L1表达分布因器官而异:淋巴结富集PD-L1高表达,骨 predominantly PD-L1阴性。
  • KRAS、TP53、MET突变与PD-L1高表达显著相关(各P < 0.001,Q < 0.001)。
  • EGFR和STK11突变与PD-L1阴性相关(P < 0.001,Q = 0.01;P = 0.001,Q < 0.001)。
  • WNT通路改变与PD-L1阴性相关(P = 0.005)。

临床怎么用

  • 解读PD-L1表达时应考虑样本取材部位。
  • 对EGFR或STK11突变患者,PD-L1对ICI疗效的预测价值有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Programmed death-ligand 1 (PD-L1) expression is the only FDA-approved biomarker for immune checkpoint inhibitors (ICIs) in patients with lung adenocarcinoma, but sensitivity is modest. Understanding the impact of molecular phenotype, clinical characteristics, and tumor features on PD-L1 expression is largely unknown and may improve prediction of response to ICI. PATIENTS AND METHODS: We evaluated patients with lung adenocarcinoma for whom PD-L1 testing and targeted next-generation sequencing (using MSK-IMPACT) was performed on the same tissue sample. Clinical and molecular features were compared across PD-L1 subgroups to examine how molecular phenotype associated with tumor PD-L1 expression. In patients treated with anti-PD-(L)1 blockade, we assessed how these interactions impacted efficacy. RESULTS: A total of 1586 patients with lung adenocarcinoma had paired PD-L1 testing and targeted next-generation sequencing. PD-L1 negativity was more common in primary compared to metastatic samples (P < 0.001). The distribution of PD-L1 expression (lymph nodes enriched for PD-L1 high; bones predominantly PD-L1 negative) and predictiveness of PD-L1 expression on ICI response varied by organ. Mutations in KRAS, TP53, and MET significantly associated with PD-L1 high expression (each P < 0.001, Q < 0.001) and EGFR and STK11 mutations associated with PD-L1 negativity (P < 0.001, Q = 0.01; P = 0.001, Q < 0.001, respectively). WNT pathway alterations also associated with PD-L1 negativity (P = 0.005). EGFR and STK11 mutants abrogated the predictive value of PD-L1 expression on ICI response. CONCLUSION: PD-L1 expression and association with ICI response vary across tissue sample sites. Specific molecular features are associated with differential expression of PD-L1 and may impact the predictive capacity of PD-L1 for response to ICIs.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Schoenfeld AJ, Rizvi H, Bandlamudi C, et al. Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas. Ann Oncol. 2020. PMID: 32178965. doi:10.1016/j.annonc.2020.01.065

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。